ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

IBI3011

A development code. Also written as “IBI3011 GROUP”.

Its studies are mostly in Gout · Arthritis, Gouty, led by Innovent Biologics.

Furthest: phase 2, since Sep 14, 20262 company-led studies, 1 open or runningNext primary completion: May 11, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics21 open or runningphase 2since Sep 14, 2026Nov 24, 2025May 11, 2027phase 2 · NCT07842497

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 24, 2025First study: phase 1 study in Acute Gout FlareFirst studyNCT07295496 · 64 enrolled · China
  2. Sep 14, 2026Phase 2 study in Acute Gouty ArthritisPhase 2 reachedNCT07842497 · 132 planned · China

Ahead

  1. May 11, 2027Primary completion: phase 2 study in Acute Gouty ArthritisNCT07842497

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07842497Acute Gouty Arthritis · China2RecruitingMay 11, 2027132
NCT07295496Acute Gout Flare · China1CompletedAug 6, 202664

How it is read

Names in the registry

  • “IBI3011”, 1 entry
  • “IBI3011 GROUP”, 1 entry

Codes read as this program: IBI3011.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.